Suzhou Fushilai Pharmaceutical Co., Ltd. (SHE:301258)

SHE:301258 Income Statement

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Sep 30, 2025	Dec 31, 2024	Dec 31, 2023	Jan 1, 2023	Jan 1, 2022	Dec 31, 2020
Operating Revenue	436.1	426.01	483.1	548.95	511.66	466.86
Other Revenue	3.46	3.46	6.19	19.26	10.03	9.98
Revenue	439.57	429.47	489.29	568.21	521.7	476.85
Revenue Growth (YoY)	6.39%	-12.23%	-13.89%	8.92%	9.40%	5.38%
Cost of Revenue	365.5	348.04	301.22	314.9	314.25	252.16
Gross Profit	74.06	81.43	188.07	253.31	207.45	224.69
Selling, General & Admin	41.69	46.58	50.89	47.65	37.44	35.32
Research & Development	34.92	40.62	40.7	41.37	28.51	22.88
Other Operating Expenses	3.57	1.89	4.78	5.1	4.11	4.28
Operating Expenses	80.22	90.59	95.18	94.54	70.41	61.98
Operating Income	-6.15	-9.16	92.89	158.77	137.04	162.71
Interest Expense	-0.07	-0.09	-0.12	-0.31	-0.45	-
Interest & Investment Income	57.12	46.94	28.96	8.2	4.62	9.32
Currency Exchange Gain (Loss)	3.36	3.36	1.48	31.6	-5.5	-6.16
Other Non Operating Income (Expenses)	0.01	-0.2	-0.19	-0.09	-0.27	-0.28
EBT Excluding Unusual Items	54.27	40.85	123.02	198.17	135.44	165.59
Gain (Loss) on Sale of Investments	32.92	-10.3	6.31	-0.86	1.61	-1.1
Gain (Loss) on Sale of Assets	-1.27	-0.93	-0.39	-	-	-
Asset Writedown	0.49	-14.36	-3.97	-1.85	-1.11	-2.06
Other Unusual Items	2.91	2.95	3.58	7.01	2.49	2.41
Pretax Income	89.33	18.21	128.54	202.46	138.44	164.83
Income Tax Expense	13.37	1.81	16.36	25.15	18.24	23.78
Net Income	75.96	16.41	112.18	177.31	120.2	141.05
Net Income to Common	75.96	16.41	112.18	177.31	120.2	141.05
Net Income Growth	302.42%	-85.38%	-36.73%	47.51%	-14.78%	-3.20%
Shares Outstanding (Basic)	90	91	92	86	69	69
Shares Outstanding (Diluted)	90	91	92	86	69	69
Shares Change (YoY)	-1.75%	-0.88%	6.83%	25.31%	-0.17%	2.00%
EPS (Basic)	0.84	0.18	1.22	2.06	1.75	2.05
EPS (Diluted)	0.84	0.18	1.22	2.06	1.75	2.05
EPS Growth	309.61%	-85.25%	-40.78%	17.71%	-14.63%	-5.09%
Free Cash Flow	-92.96	-58.25	53.15	101.08	118.98	101.16
Free Cash Flow Per Share	-1.03	-0.64	0.58	1.17	1.73	1.47
Dividend Per Share	0.091	0.091	0.600	0.580	0.400	0.700
Dividend Growth	-84.83%	-84.83%	3.45%	45.00%	-42.86%	-7.90%
Gross Margin	16.85%	18.96%	38.44%	44.58%	39.77%	47.12%
Operating Margin	-1.40%	-2.13%	18.98%	27.94%	26.27%	34.12%
Profit Margin	17.28%	3.82%	22.93%	31.20%	23.04%	29.58%
Free Cash Flow Margin	-21.15%	-13.56%	10.86%	17.79%	22.81%	21.21%
EBITDA	35.59	38.69	148.89	210.37	183.15	196.29
EBITDA Margin	8.10%	9.01%	30.43%	37.02%	35.11%	41.16%
D&A For EBITDA	41.74	47.85	56	51.61	46.11	33.58
EBIT	-6.15	-9.16	92.89	158.77	137.04	162.71
EBIT Margin	-1.40%	-2.13%	18.98%	27.94%	26.27%	34.12%
Effective Tax Rate	14.97%	9.92%	12.73%	12.43%	13.18%	14.43%
Revenue as Reported	439.57	429.47	489.29	568.21	521.7	476.85
Advertising Expenses	-	-	-	1.19	-	-

Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.